Baidu
map

PNAS:FGFR4 ,MAP3K9和PAK5可能成为非小细胞肺癌(NSCLC)的潜在治疗靶点

2013-07-13 MedSci MedSci原创

       肺癌是最难研究的癌症之一,有一半的非小细胞肺癌仍然不清楚其潜在遗传改变。当前科学家可以用药物或其他治疗靶向的遗传标记非常之少。而改善肺癌的生存是目前研究人员的当务之急。  日前,英国癌症研究中心的研究人员首次利用一种高效的新筛选策略,确定了最常见肺癌类型肿瘤细胞中的基因缺陷。这项研究为个体化治疗患者肿瘤,实时鉴别潜在的药物靶点提供了一种新方法。

肺癌
  

    
肺癌是最难研究的癌症之一,有一半的非小细胞肺癌仍然不清楚其潜在遗传改变。当前科学家可以用药物或其他治疗靶向的遗传标记非常之少。而改善肺癌的生存是目前研究人员的当务之急。

  日前,英国癌症研究中心的研究人员首次利用一种高效的新筛选策略,确定了最常见肺癌类型肿瘤细胞中的基因缺陷。这项研究为个体化治疗患者肿瘤,实时鉴别潜在的药物靶点提供了一种新方法。

  在这项刊登在PNAS杂志上的研究中,科学家们对实验室中培养的 6 种不同的非小细胞肺癌(NSCLC)细胞系进行了研究,每种细胞系已知携带了超过60个基因缺陷。为了确切地查明哪些缺陷驱动了癌症,科学家们特异采用依次关闭一个不同的缺陷基因的方法,来观察了它们对于细胞生长的影响。

  最终,研究小组发现有三个重要的基因: FGFR4 、 MAP3K9 和 PAK5 发生缺陷会导致生成过度活化的蛋白,由此向细胞发生信号导致其生长失控。

  研究人员表示,新技术使得研究人员能够开始绘制出最有可能驱动这些癌症生长的基因缺陷的图谱。这一重要的研究工作将推动更早实现肺癌患者个体化治疗。了解驱动个体患者癌症的遗传缺陷,将有助于确保研究人员在正确的时间得到正确的治疗。

原始出处:

Fawdar S, Trotter EW, Li Y, Stephenson NL, Hanke F, Marusiak AA, Edwards ZC, Ientile S, Waszkowycz B, Miller CJ, Brognard J. Targeted genetic dependency screen facilitates identification of actionable mutations in FGFR4, MAP3K9, and PAK5 in lung cancer.Proc Natl Acad Sci U S A. 2013 Jul 8.

PDF文件下载:1305207110.full.pdf

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2059437, encodeId=53ba205943e4f, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Apr 17 06:17:00 CST 2014, time=2014-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895302, encodeId=1cf3189530219, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Thu Aug 22 01:17:00 CST 2013, time=2013-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855411, encodeId=106f1855411c4, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Wed Aug 21 20:17:00 CST 2013, time=2013-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483057, encodeId=d1b2148305ef3, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7397, encryptionId=5dcbe397d2, topicName=FGFR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=31fb7872570, createdName=12498c24m71暂无昵称, createdTime=Sun Jul 14 15:17:00 CST 2013, time=2013-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534212, encodeId=f4141534212a0, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Sun Jul 14 15:17:00 CST 2013, time=2013-07-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2059437, encodeId=53ba205943e4f, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Apr 17 06:17:00 CST 2014, time=2014-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895302, encodeId=1cf3189530219, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Thu Aug 22 01:17:00 CST 2013, time=2013-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855411, encodeId=106f1855411c4, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Wed Aug 21 20:17:00 CST 2013, time=2013-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483057, encodeId=d1b2148305ef3, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7397, encryptionId=5dcbe397d2, topicName=FGFR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=31fb7872570, createdName=12498c24m71暂无昵称, createdTime=Sun Jul 14 15:17:00 CST 2013, time=2013-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534212, encodeId=f4141534212a0, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Sun Jul 14 15:17:00 CST 2013, time=2013-07-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2059437, encodeId=53ba205943e4f, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Apr 17 06:17:00 CST 2014, time=2014-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895302, encodeId=1cf3189530219, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Thu Aug 22 01:17:00 CST 2013, time=2013-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855411, encodeId=106f1855411c4, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Wed Aug 21 20:17:00 CST 2013, time=2013-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483057, encodeId=d1b2148305ef3, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7397, encryptionId=5dcbe397d2, topicName=FGFR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=31fb7872570, createdName=12498c24m71暂无昵称, createdTime=Sun Jul 14 15:17:00 CST 2013, time=2013-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534212, encodeId=f4141534212a0, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Sun Jul 14 15:17:00 CST 2013, time=2013-07-14, status=1, ipAttribution=)]
    2013-08-21 drwjr
  4. [GetPortalCommentsPageByObjectIdResponse(id=2059437, encodeId=53ba205943e4f, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Apr 17 06:17:00 CST 2014, time=2014-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895302, encodeId=1cf3189530219, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Thu Aug 22 01:17:00 CST 2013, time=2013-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855411, encodeId=106f1855411c4, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Wed Aug 21 20:17:00 CST 2013, time=2013-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483057, encodeId=d1b2148305ef3, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7397, encryptionId=5dcbe397d2, topicName=FGFR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=31fb7872570, createdName=12498c24m71暂无昵称, createdTime=Sun Jul 14 15:17:00 CST 2013, time=2013-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534212, encodeId=f4141534212a0, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Sun Jul 14 15:17:00 CST 2013, time=2013-07-14, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2059437, encodeId=53ba205943e4f, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Apr 17 06:17:00 CST 2014, time=2014-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895302, encodeId=1cf3189530219, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Thu Aug 22 01:17:00 CST 2013, time=2013-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855411, encodeId=106f1855411c4, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Wed Aug 21 20:17:00 CST 2013, time=2013-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483057, encodeId=d1b2148305ef3, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7397, encryptionId=5dcbe397d2, topicName=FGFR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=31fb7872570, createdName=12498c24m71暂无昵称, createdTime=Sun Jul 14 15:17:00 CST 2013, time=2013-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534212, encodeId=f4141534212a0, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Sun Jul 14 15:17:00 CST 2013, time=2013-07-14, status=1, ipAttribution=)]
    2013-07-14 liuyiping

相关资讯

Ann Oncol:老年肺癌患者术后化疗不影响生存质量

  韩国学者的一项研究显示,老年非小细胞肺癌(NSCLC)患者可能存在其它共存病,以及身体机能下降,术后的辅助化疗对老年病人的健康相关生存质量(HRQOL)无显著影响,且治疗前后的HRQOL无显著差别。   该研究于2008年10月到2011年10月期间纳入65岁以上(N=66)和65以下(N=73)的NSCLC患者,比较其化疗后的HRQOL。   结果显示,术后的辅助化疗对老年病人的健康相关

CANCER:在线支持系统可减轻NSCLC患者忧虑

  通过与互联网支持比较,美国学者研究了一种在线支持系统(综合性健康增强支持系统[CHESS])减轻非小细胞肺癌(NSCLC)患者身体症状相关性忧虑的有效性,结果表明,在线支持系统可能会减轻患者身体症状相关性忧虑,但其能否带来生存获益仍需要进一步研究。   该研究纳入285对非正式护理人员和患者,被随机分配到两组,一组接受标准护理和互联网使用的培训与操作(互联网组),另一组接受标准护

AATS 2013:NSCLC手术切缘增至15mm可降低复发风险

  明尼阿波利斯——美国胸外科学会(AATS)2013年会上报告的一项针对474例非小细胞肺癌(NSCLC)连续病例数据分析显示,楔形切除术手术切缘宽度增至15 mm可显著降低局部复发风险,但超过15 mm未见额外受益。   波士顿布里格姆妇女医院外科研究员Kamran Mohiuddin博士报告称,与切缘宽度为5 mm相比,切缘宽度为10 mm

Ann Thorac Surg:术中冰冻切片在肺癌切除术中作用有限

  非小细胞肺癌(NSCLC)切除后支气管残端阳性不利于患者的术后生存。为了确保R0 切除,胸外科医生通常采用术中冰冻切片分析支气管残端。然而,对于术中冰冻切片在非小细胞肺癌切除患者中是否应该常规应用,这方面的研究较少。针对这种情况,来美国佐治亚州亚特兰大市埃默里大学医学院普胸外科的Fernandez博士等人进行了一项研究,研究结果发表于2013年6月的《胸外科年鉴》(Ann&n

Lung Cancer:EGFR突变与癌症家族史有密切关系

随着表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)如:易瑞沙、特罗凯等广泛的应用,越来越多的研究表明EGFR突变与癌症家族史有着密切的关系。来自同济大学上海肺科医院的周彩存等针对中国地区的患者进行了一项前沿性分析实验,该研究结果发表在2013年5月30日的肺癌(Lung Cancer)杂志。该研究结果表明具有癌症家族史的非小细胞肺癌患者尤其是具有肺癌家族史的患者,具有较高的EGFR突变率。

ACIEE:针对非小细胞肺癌EGFRT790M突变体的靶向化合物被设计

7月5日,记者在中科院广州生物医药与健康研究院获悉,该院科学家在克服非小细胞肺癌耐药研究方面获得新突破。相关结果在美国《药物化学杂志》和德国《应用化学》上在线发表。 肺癌是严重威胁人类健康的重大疾病,非小细胞肺癌则占所有类型肺癌的85%以上。目前,表皮生长因子(EGFR)受体抑制剂易瑞沙(吉非替尼)和特罗凯(埃罗替尼)等已在临床治疗非小细胞肺癌中获得巨大成功,但其耐药问题也日益突出。第二

Baidu
map
Baidu
map
Baidu
map